AN2 Therapeutics (ANTX) and the non-profit medical research organization Drugs for Neglected Diseases initiative announced a collaboration to advance clinical development of AN2-502998, AN2’s oral drug candidate in development for the treatment of chronic Chagas disease.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANTX: